25 años de CENTIS. Pandemia y Radiofármacos
Contenido principal del artículo
Resumen
Próximo a su 25 aniversario CENTIS reflexiona sobre su quehacer en el contexto de los trastornos que causa la COVID-19. Con ese propósito se examinan el estado de la medicina nuclear y la radiofarmacia antes y durante la epidemia y sus perspectivas de desarrollo. La producción global de radiofármacos continúa siendo una industria consolidada y aunque la pandemia afecta a esta esfera, la presencia de otras enfermedades no cesa, por lo que los servicios de medicina nuclear esenciales y críticos siguen siendo necesarios. Se espera su paulatina reapertura y que se retome con más fuerza la investigación, dado que la COVID-19 es tan compleja y se asocia a tantos factores que constituye, en perspectiva, terreno virgen para las técnicas diagnósticas en medicina nuclear. Ha de permanecer asimismo el papel de los radiofármacos terapéuticos en un grupo importante de enfermedades, en cáncer sobre todo. El Centro de Isótopos pone por ello énfasis tanto en la consolidación, bajo buenas prácticas, de la producción y el suministro de radiofármacos, como en el desarrollo de nuevos productos. Ambos aspectos se basan principalmente en dos radionúclidos: Tc-99m e Y-90.
Detalles del artículo
Cómo citar
Cruz Arencibia, J., Leyva Montaña, R., & Morín Zorrilla, J. (1). 25 años de CENTIS. Pandemia y Radiofármacos. Nucleus, (67). Recuperado a partir de http://nucleus.cubaenergia.cu/index.php/nucleus/article/view/698
Número
Sección
Panorama Nuclear
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial 4.0.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista. Bajo esta licencia el autor será libre de:
- Compartir — copiar y redistribuir el material en cualquier medio o formato
- Adaptar — remezclar, transformar y crear a partir del material
- El licenciador no puede revocar estas libertades mientras cumpla con los términos de la licencia
Bajo las siguientes condiciones:
- Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
- NoComercial — No puede utilizar el material para una finalidad comercial.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
La Revista Nucleus solo aceptará contribuciones que no hayan sido previamente publicados y/o procesados, por otra publicación. Cualquier violación ese sentido será considerada una falta grave por parte del autor principal lo cual será objeto valoración por parte del Consejo Editorial, el cual dictaminará al respecto.
Citas
[1] Nuclear Medicine/Radiopharmaceuticals Market. Nuclear medicine/radiopharmaceuticals market by type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology, Cardiology) - Global Forecast to 2024. [website]. Available in: https://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417. [access: june 20, 2020].
[2] Radiopharmaceuticals Market. 2019 analysis and review of radiopharmaceuticals market by application - oncology, cardiology, gastroenterology, neuroendocrinology, neurology, and nephrology for 2019 - 2029 [website]. Available in: https://www.futuremarketinsights.com/reports/radiopharmaceuticals-market. [access: june june 20, 2020].
[3] Global Radiopharmaceuticals Market - Industry Trends - Forecast to 2026. https://www.databridgemarketresearch.com/reports/global-radiopharmaceuticals-market. [access: june 19, 2020].
[4] National Academies of Sciences, Engineering, and Medicine. Opportunities and approaches for supplying molybdenum-99 and associated medical isotopes to global markets. Proceedings of a Symposium. Washington, DC: The National Academies Press, 2018. https://doi.org/10.17226/24909.
[5] OPS/OMS. Repositorio Institucional para el Intercambio de Información (IRIS). Indicadores básicos 2019. Tendencias de salud en Las Américas [sitio web]. Disponible en: Disponible en: https://iris.paho.org/handle/10665.2/51543 [access: july 28, 2020].
[6] Market Data Forecast. Latin America nuclear medicine radiopharmaceuticals market research report - segmented by diagnostics, by therapeutics, by application, by country (Mexico, Brazil, Argentina, Chile and Rest of Latin America) - Industry Analysis, Size, Share, Growth, Trends, Forecasts (2019-2024) [website]. Available in: https://www.marketdataforecast.com/market-reports/latin-america-nuclear-medicine-radiopharmaceuticals-market. [access: june 25, 2020].
[7] PÁEZ D, ORELLANA P, GUTIÉRREZ C, RAMIREZ R, MUT F. AND TORRES L . Current status of nuclear medicine practice in latin america and the caribbean. J Nucl Med. 2015; 56(10): 1629-1634
[8] HENNRICH U, KOPKA K. Lutathera®: The First FDA- and EMA-Approved radiopharmaceutical for peptide receptor radionuclide therapy. pharmaceuticals (Basel) 2019; 12(3): 114. doi: 10.3390/ph12030114 3390/ph12030114 http://www.mdpi.com/journal/pharmaceuticals. [access: february 15, 2020].
[9] SCHWARZ SW, CLARKE B. Perspective on how the fda should review diagnostic radiopharmaceuticals. J Nucl Med . 2018; 59(6): 865-867.
[10] SCHWARZ SW, DECRISTOFORO C, et. al. Harmonization of U.S., European Union, and Canadian first-in-human regulatory requirements for radiopharmaceuticals: is this possible? J Nucl Med . 2019; 60(2): 158-166. doi: 10.2967/jnumed.118.209460.
[11] SCHWARZ SW, DECRISTOFORO C. US and EU radiopharmaceutical diagnostic and therapeutic nonclinical study requirements for clinical trials authorizations and marketing authorizations. EJNMMI Radiopharmacy and Chemistry. 2019; 4:10. https://doi.org/10.1186/s41181-019-0059-2.
[12] SHARMA N, KAUR H & SHARMA RK. Radiopharmaceuticals regulations: current scenario and the way forward. Applied Clinical Research, Clinical Trials & Regulatory Affairs, 2017; 4: 1-12.
[13] DECRISTOFORO C & LYASHCHENKO SK. Recommendations for conducting clinical trials with radiopharmaceuticals. In: nuclear medicine textbook. August, 2019. https://doi.org/10.1007/978-3-319-95564-3_41.
[14] NEELS O, PATT M & DECRISTOFORO C. Radionuclides: medicinal products or rather starting materials?. EJNMMI Radiopharmacy and Chemistry . 2019; 4: 22. https://doi.org/10.1186/s41181-019-0074-3.
[15] SHARMA S, SANYOG J, et. al. Intricacies in the approval of radiopharmaceuticals - regulatory perspectives and the way forward. Current Science. 2019, 116(1): 47-65. doi: 10.18520/cs/v116/i1/47-55.
[16] U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Oncology therapeutic radiopharmaceuticals: nonclinical studies and labeling recommendations guidance for industry (pharmacology/toxicology). August, 2019.
[17] Food and Drug Administration (FDA). E17 General principles for planning and design of multiregional clinical trials. FDA, 2018. Available at: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM519603.pdf. [access: july 24, 2020].
[18] AuntMinnie.com [website]. https://www.auntminnie.com/index.aspx?sec=dis&ItemID=129109, 129130, 128809, 128819, 128750, 128734, 128865, 129176, 129177, 129073, 129191, 129316, 129345, 129349, 129357 . [access: June, 2020].
[19] MERKEL C, WHICHER CH, BOMANJI J, HERRMANN3 K, et. al. Realising the potential of radioligand therapy: policy solutions for the barriers to implementation across Europe. European Journal of Nuclear Medicine and Molecular Imaging. 2020; 47: 1335-1339 https://doi.org/10.1007/s00259-020-04745-7
[20] PAEZ D, GNANASEGARAN G, FANTI S, et. al. COVID-19 pandemic: guidance for nuclear medicine departments. Eur J Nucl Med Mol Imaging. 2020; 47: 1615-1619. https://doi.org/10.1007/s00259-020-04825-8
[21] HUANG HL, GNANASEGARAN G, PAEZ D, et. al. Nuclear medicine services after COVID-19: gearing up back to normality. Eur J Nucl Med Mol Imaging . 2020; 47: 2048-2053. https://doi.org/10.1007/s00259-020-04848-1.
[22] International Atomic Energy Agency (IAEA). COVID-19 pandemic: technical guidance for nuclear medicine departments. Vienna: IAEA, July 2020. 50 p.
[23] Human Health Campus [website]. https://humanhealth.iaea.org/HHW/ Global Radiopharmaceuticals Market (COVID 19 UPDATE) Overview by Type, Technological Advancements & Forecast to 2027,https://jewishlifenews.com/uncategorized/global-radiopharmaceuticals-market-covid-19-update-overview-by-type-technological-advancements-forecast-to-2027/
[24] Radiopharmaceuticals Market Analysis 2020- Industry Trend, Revenue, Top Players, Size, Share, COVID-19 Impact, Region, Feasibility, Economics, Pricing Analysis, Opportunities, Forecast to 2025. Published: June 12, 2020 https://www.marketwatch.com/press-release/nuclear-medicine-or-radiopharmaceuticals-market-analysis-2020--industry-trend-revenue-top-players-size-share-covid-19-impact-region-feasibility-economics-pricing-analysis-opportunities-forecast-to-2025
[25] BOSCHI A., LICIA UCCELLI L. & MARTINI P. A picture of modern Tc-99m radiopharmaceuticals: production, chemistry, and applications in molecular imaging. Review. Appl. Sci. 2019; 9: 2526-2542. doi: 10.3390/app9122526.
[26] PILLAI MRA, NANABALA R, JOY A, SASIKUMAR A, KNAPP FF. Radiolabeled enzyme inhibitors and binding agents targeting psma: effective theranostic tools for imaging and therapy of prostate cancer. Nucl Med Biol. 2016; 43(11): 692-720 doi: 10.1016/j.nucmedbio.2016.08.006.
[27] LEE WW. Clinical applications of technetium-99m quantitative single-photon emission computed tomography/computed tomography. Nucl Med Mol Imaging . 2019; 53(3): 172-181. doi.org/10.1007/s13139-019-00588-9.
[28] MANTEL I, WILLIAMS J. An introduction to newer PET diagnostic agents and related therapeutic radiopharmaceuticals. J of Nucl. Med. and Technol. 2019; 47(3): 203-209 doi:10.2967/jnmt.118.224022.
[29] SWACHCHHANDA S, PANKAJ N, et. al. Axumin positron emission tomography: novel agent for prostate cancer biochemical recurrence. J Clin Imaging Sci. 2019; 9: 49. doi: 10.25259/JCIS_139_2019.
[30] PETRONI D, MENICHETTI L, POLI M. Historical and radiopharmaceutical relevance of [18F] FDG. Journal of Radioanalytical and Nuclear Chemistry. 2020. https://doi.org/10.1007/s10967-020-07013-y.
[31] SOLNES LB, WERNER RW, JONES KM, SADAGHIANI MS. Theranostics: leveraging molecular imaging and therapy to impact patient management and secure the future of nuclear medicine. J. of Nucl. Med. 2020; 61: 311-318. doi:10.2967/jnumed.118.220665.
[32] KENDI AT, HALFDANARSON TR, PACKARD A, DUNDAR A, SUBRAMANIAM RM. Therapy With 177Lu-DOTATATE: clinical implementation and impact on care of patients with neuroendocrine tumors. Review. Nucl. Med. and Mol. Imaging. 2019; doi.org/10.2214/AJR.19.21123.
[33] ALBERTI RAMÍREZ A, GARCÍA RODRÍGUEZ E, CRUZ ARENCIBIA J, MORÍN ZORRILLA J. Fósforo-32 e Itrio-90 como opciones en el tratamiento del dolor óseo metastásico. Nucleus. 2016; (60): 24-28.
[34] SOWA-STASZCZAK A, et. al. Efficacy and safety of 90Y-DOTATATE, therapy in neuroendocrine tumours. Polish Journal of Endocrinology. 2011; 62: 5.
[35] CWIKLA JB, et. al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Annals of Oncology. 2010; 21: 787-794.
[34] SCHULTZ WA. Molecular Biology of Human Cancers. Springer Science + Business Media, Inc. 2005.
[36] HICKS RJ, JACKSON P, KONG G, WARE RE, et. al. 64Cu-SARTATE PET Imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. J Nucl Med . 2019; 60: 777-785. doi: 10.2967/jnumed.118.217745.
[37] ClinicalTrials.gov [website] Identifier: NCT04023331. 67Cu-SARTATE™ peptide receptor radionuclide therapy administered to pediatric patients with high-risk neuroblastoma. https://www.smartpatients.com/trials/NCT04023331 . [access: August, 2020].
[2] Radiopharmaceuticals Market. 2019 analysis and review of radiopharmaceuticals market by application - oncology, cardiology, gastroenterology, neuroendocrinology, neurology, and nephrology for 2019 - 2029 [website]. Available in: https://www.futuremarketinsights.com/reports/radiopharmaceuticals-market. [access: june june 20, 2020].
[3] Global Radiopharmaceuticals Market - Industry Trends - Forecast to 2026. https://www.databridgemarketresearch.com/reports/global-radiopharmaceuticals-market. [access: june 19, 2020].
[4] National Academies of Sciences, Engineering, and Medicine. Opportunities and approaches for supplying molybdenum-99 and associated medical isotopes to global markets. Proceedings of a Symposium. Washington, DC: The National Academies Press, 2018. https://doi.org/10.17226/24909.
[5] OPS/OMS. Repositorio Institucional para el Intercambio de Información (IRIS). Indicadores básicos 2019. Tendencias de salud en Las Américas [sitio web]. Disponible en: Disponible en: https://iris.paho.org/handle/10665.2/51543 [access: july 28, 2020].
[6] Market Data Forecast. Latin America nuclear medicine radiopharmaceuticals market research report - segmented by diagnostics, by therapeutics, by application, by country (Mexico, Brazil, Argentina, Chile and Rest of Latin America) - Industry Analysis, Size, Share, Growth, Trends, Forecasts (2019-2024) [website]. Available in: https://www.marketdataforecast.com/market-reports/latin-america-nuclear-medicine-radiopharmaceuticals-market. [access: june 25, 2020].
[7] PÁEZ D, ORELLANA P, GUTIÉRREZ C, RAMIREZ R, MUT F. AND TORRES L . Current status of nuclear medicine practice in latin america and the caribbean. J Nucl Med. 2015; 56(10): 1629-1634
[8] HENNRICH U, KOPKA K. Lutathera®: The First FDA- and EMA-Approved radiopharmaceutical for peptide receptor radionuclide therapy. pharmaceuticals (Basel) 2019; 12(3): 114. doi: 10.3390/ph12030114 3390/ph12030114 http://www.mdpi.com/journal/pharmaceuticals. [access: february 15, 2020].
[9] SCHWARZ SW, CLARKE B. Perspective on how the fda should review diagnostic radiopharmaceuticals. J Nucl Med . 2018; 59(6): 865-867.
[10] SCHWARZ SW, DECRISTOFORO C, et. al. Harmonization of U.S., European Union, and Canadian first-in-human regulatory requirements for radiopharmaceuticals: is this possible? J Nucl Med . 2019; 60(2): 158-166. doi: 10.2967/jnumed.118.209460.
[11] SCHWARZ SW, DECRISTOFORO C. US and EU radiopharmaceutical diagnostic and therapeutic nonclinical study requirements for clinical trials authorizations and marketing authorizations. EJNMMI Radiopharmacy and Chemistry. 2019; 4:10. https://doi.org/10.1186/s41181-019-0059-2.
[12] SHARMA N, KAUR H & SHARMA RK. Radiopharmaceuticals regulations: current scenario and the way forward. Applied Clinical Research, Clinical Trials & Regulatory Affairs, 2017; 4: 1-12.
[13] DECRISTOFORO C & LYASHCHENKO SK. Recommendations for conducting clinical trials with radiopharmaceuticals. In: nuclear medicine textbook. August, 2019. https://doi.org/10.1007/978-3-319-95564-3_41.
[14] NEELS O, PATT M & DECRISTOFORO C. Radionuclides: medicinal products or rather starting materials?. EJNMMI Radiopharmacy and Chemistry . 2019; 4: 22. https://doi.org/10.1186/s41181-019-0074-3.
[15] SHARMA S, SANYOG J, et. al. Intricacies in the approval of radiopharmaceuticals - regulatory perspectives and the way forward. Current Science. 2019, 116(1): 47-65. doi: 10.18520/cs/v116/i1/47-55.
[16] U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Oncology therapeutic radiopharmaceuticals: nonclinical studies and labeling recommendations guidance for industry (pharmacology/toxicology). August, 2019.
[17] Food and Drug Administration (FDA). E17 General principles for planning and design of multiregional clinical trials. FDA, 2018. Available at: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM519603.pdf. [access: july 24, 2020].
[18] AuntMinnie.com [website]. https://www.auntminnie.com/index.aspx?sec=dis&ItemID=129109, 129130, 128809, 128819, 128750, 128734, 128865, 129176, 129177, 129073, 129191, 129316, 129345, 129349, 129357 . [access: June, 2020].
[19] MERKEL C, WHICHER CH, BOMANJI J, HERRMANN3 K, et. al. Realising the potential of radioligand therapy: policy solutions for the barriers to implementation across Europe. European Journal of Nuclear Medicine and Molecular Imaging. 2020; 47: 1335-1339 https://doi.org/10.1007/s00259-020-04745-7
[20] PAEZ D, GNANASEGARAN G, FANTI S, et. al. COVID-19 pandemic: guidance for nuclear medicine departments. Eur J Nucl Med Mol Imaging. 2020; 47: 1615-1619. https://doi.org/10.1007/s00259-020-04825-8
[21] HUANG HL, GNANASEGARAN G, PAEZ D, et. al. Nuclear medicine services after COVID-19: gearing up back to normality. Eur J Nucl Med Mol Imaging . 2020; 47: 2048-2053. https://doi.org/10.1007/s00259-020-04848-1.
[22] International Atomic Energy Agency (IAEA). COVID-19 pandemic: technical guidance for nuclear medicine departments. Vienna: IAEA, July 2020. 50 p.
[23] Human Health Campus [website]. https://humanhealth.iaea.org/HHW/ Global Radiopharmaceuticals Market (COVID 19 UPDATE) Overview by Type, Technological Advancements & Forecast to 2027,https://jewishlifenews.com/uncategorized/global-radiopharmaceuticals-market-covid-19-update-overview-by-type-technological-advancements-forecast-to-2027/
[24] Radiopharmaceuticals Market Analysis 2020- Industry Trend, Revenue, Top Players, Size, Share, COVID-19 Impact, Region, Feasibility, Economics, Pricing Analysis, Opportunities, Forecast to 2025. Published: June 12, 2020 https://www.marketwatch.com/press-release/nuclear-medicine-or-radiopharmaceuticals-market-analysis-2020--industry-trend-revenue-top-players-size-share-covid-19-impact-region-feasibility-economics-pricing-analysis-opportunities-forecast-to-2025
[25] BOSCHI A., LICIA UCCELLI L. & MARTINI P. A picture of modern Tc-99m radiopharmaceuticals: production, chemistry, and applications in molecular imaging. Review. Appl. Sci. 2019; 9: 2526-2542. doi: 10.3390/app9122526.
[26] PILLAI MRA, NANABALA R, JOY A, SASIKUMAR A, KNAPP FF. Radiolabeled enzyme inhibitors and binding agents targeting psma: effective theranostic tools for imaging and therapy of prostate cancer. Nucl Med Biol. 2016; 43(11): 692-720 doi: 10.1016/j.nucmedbio.2016.08.006.
[27] LEE WW. Clinical applications of technetium-99m quantitative single-photon emission computed tomography/computed tomography. Nucl Med Mol Imaging . 2019; 53(3): 172-181. doi.org/10.1007/s13139-019-00588-9.
[28] MANTEL I, WILLIAMS J. An introduction to newer PET diagnostic agents and related therapeutic radiopharmaceuticals. J of Nucl. Med. and Technol. 2019; 47(3): 203-209 doi:10.2967/jnmt.118.224022.
[29] SWACHCHHANDA S, PANKAJ N, et. al. Axumin positron emission tomography: novel agent for prostate cancer biochemical recurrence. J Clin Imaging Sci. 2019; 9: 49. doi: 10.25259/JCIS_139_2019.
[30] PETRONI D, MENICHETTI L, POLI M. Historical and radiopharmaceutical relevance of [18F] FDG. Journal of Radioanalytical and Nuclear Chemistry. 2020. https://doi.org/10.1007/s10967-020-07013-y.
[31] SOLNES LB, WERNER RW, JONES KM, SADAGHIANI MS. Theranostics: leveraging molecular imaging and therapy to impact patient management and secure the future of nuclear medicine. J. of Nucl. Med. 2020; 61: 311-318. doi:10.2967/jnumed.118.220665.
[32] KENDI AT, HALFDANARSON TR, PACKARD A, DUNDAR A, SUBRAMANIAM RM. Therapy With 177Lu-DOTATATE: clinical implementation and impact on care of patients with neuroendocrine tumors. Review. Nucl. Med. and Mol. Imaging. 2019; doi.org/10.2214/AJR.19.21123.
[33] ALBERTI RAMÍREZ A, GARCÍA RODRÍGUEZ E, CRUZ ARENCIBIA J, MORÍN ZORRILLA J. Fósforo-32 e Itrio-90 como opciones en el tratamiento del dolor óseo metastásico. Nucleus. 2016; (60): 24-28.
[34] SOWA-STASZCZAK A, et. al. Efficacy and safety of 90Y-DOTATATE, therapy in neuroendocrine tumours. Polish Journal of Endocrinology. 2011; 62: 5.
[35] CWIKLA JB, et. al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Annals of Oncology. 2010; 21: 787-794.
[34] SCHULTZ WA. Molecular Biology of Human Cancers. Springer Science + Business Media, Inc. 2005.
[36] HICKS RJ, JACKSON P, KONG G, WARE RE, et. al. 64Cu-SARTATE PET Imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. J Nucl Med . 2019; 60: 777-785. doi: 10.2967/jnumed.118.217745.
[37] ClinicalTrials.gov [website] Identifier: NCT04023331. 67Cu-SARTATE™ peptide receptor radionuclide therapy administered to pediatric patients with high-risk neuroblastoma. https://www.smartpatients.com/trials/NCT04023331 . [access: August, 2020].